The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization
Journal of Gynecologic Oncology · 2023
DOI: 10.3802/jgo.2023.34.e33 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2023. Verfasst von David Tan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore. Hauptthemen laut MEDLINE: Genital Neoplasms, Female. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND AND PURPOSEWith a population of 4.4 billion, the Asia-Pacific region accounts for more than half of the world's population.Moreover, it is the largest region in the world by total gross domestic product (GDP) [1].Nonetheless, significant disparities in healthcare infrastructure and provision exist across the region due to the diversity of socio-economic resources in each country.Overall, the burden of cancer incidence and mortality is rapidly growing in Asia.Furthermore, according to the global cancer statistics, Asia accounted for one-half of all new cancer cases and cancer deaths in 2020 [2].The Asia-Pacific Gynecologic Oncology Trials Group (APGOT) was founded in November 2019 to bring attention to this issue.'The ultimate goal of the APGOT' is to provide the best treatment to patients with gynecologic cancers on the basis of robust scientific evidence and enable every patient in every Asian-Pacific region to access a clinical trial (Fig. 1A).The APGOT comprises a research network of international and regional clinical trial units that coordinates and promotes clinical trials within the Asia-Pacific region for patients with gynecologic cancers.This coordination is particularly relevant for academic clinical trials, translational research, research on rare diseases, and clinical trials sponsored by the industry to perform multicenter international studies in the Asia-Pacific region.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore.
- Cancer Science Institute, National University of Singapore, Singapore.
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Department of Palliative Medicine and Advanced Clinical Oncology, IMSUT Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan. fujiwaranorikorn@gmail.com.
- Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
- Department of Medical Oncology, Concord Hospital, Concord, NSW, Australia.
ORCID-Profile: David Tan, Noriko Fujiwara, Keiichi Fujiwara, Philip Beale, Jae-Weon Kim, Joseph Ng, Se Ik Kim, Alison Evans, Byoung-Gie Kim
Zitieren
APA
Tan, D., Fujiwara, N., Fujiwara, K., Beale, P., Kim, J. W., Ng, J., Kim, S. I., Evans, A., Kim, B. G., & Asia-Pacific Gynecologic Oncology Trials Group (APGOT) (2023). The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2023.34.e33
Vancouver
Tan D, Fujiwara N, Fujiwara K, Beale P, Kim JW, Ng J, et al. The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization. Journal of Gynecologic Oncology. 2023. doi:10.3802/jgo.2023.34.e33
BibTeX
@article{Tan2023,
author = {Tan, David and Fujiwara, Noriko and Fujiwara, Keiichi and Beale, Philip and Kim, Jae-Weon and Ng, Joseph and Kim, Se Ik and Evans, Alison and Kim, Byoung-Gie and Asia-Pacific Gynecologic Oncology Trials Group (APGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)},
title = {The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization},
journal = {Journal of Gynecologic Oncology},
year = {2023},
doi = {10.3802/jgo.2023.34.e33}
}
EUVIMED